상세 보기
International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer: MONET1
- Scagliotti, Giorgio V.;
- Vynnychenko, Ihor;
- Park, Keunchil;
- Ichinose, Yukito;
- Kubota, Kaoru;
- 외 13명
WEB OF SCIENCE
156SCOPUS
167초록
Purpose We evaluated whether motesanib (a selective oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3; platelet-derived growth factor receptor; and Kit) combined with carboplatin/paclitaxel improved overall survival (OS) versus chemotherapy alone in patients with nonsquamous non-small-cell lung cancer (NSCLC) and in the subset of patients with adenocarcinoma. Patients and Methods Patients with stage IIIB/IV or recurrent nonsquamous NSCLC (no prior systemic therapy for advanced disease) were randomly assigned 1: 1 to carboplatin (area under the curve, 6 mg/ml.min) and paclitaxel (200 mg/m(2)) intravenously for up to six 3-week cycles plus either motesanib 125 mg (arm A) or placebo (arm B) once daily orally. OS was the primary end point. Secondary end points included progression-free survival (PFS), objective response rate (ORR), adverse events (AEs), and association between placental growth factor (PLGF) change and OS. Results A total of 1,090 patients with nonsquamous NSCLC were randomly assigned (arms A/B, n = 541 of 549); of those, 890 had adenocarcinoma (n = 448 of 442). Median OS in arms A and B was 13.0 and 11.0 months, respectively (hazard ratio [HR], 0.90; 95% CI, 0.78 to 1.04; P = .14); median OS for the adenocarcinoma subset was 13.5 and 11.0 months, respectively (HR, 0.88; 95% CI, 0.75 to 1.03; P = .11). In descriptive analyses (arms A v B), median PFS was 5.6 months versus 5.4 months (P = <.001); ORR was 40% versus 26% (P < .001). There was no association between PLGF change and OS in arm A. The incidence of grade >= 3 AEs (arms A and B, 73% and 59%, respectively) and grade 5 AEs (14% and 9%, respectively) was higher with motesanib treatment. Conclusion Motesanib plus carboplatin/paclitaxel did not significantly improve OS over carboplatin/paclitaxel alone in patients with advanced nonsquamous NSCLC or in the adenocarcinoma subset.
키워드
- 제목
- International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer: MONET1
- 저자
- Scagliotti, Giorgio V.; Vynnychenko, Ihor; Park, Keunchil; Ichinose, Yukito; Kubota, Kaoru; Blackhall, Fiona; Pirker, Robert; Galiulin, Rinat; Ciuleanu, Tudor-Eliade; Sydorenko, Oleksandr; Dediu, Mircea; Papai-Szekely, Zsolt; Martinez Banaclocha, Natividad; McCoy, Sheryl; Yao, Bin; Hei, Yong-jiang; Galimi, Francesco; Spigel, David R.
- 발행일
- 2012-08-10
- 유형
- Article
- 권
- 30
- 호
- 23
- 페이지
- 2829 ~ 2836
- 언어
- ENG
- 출판사
- American Society of Clinical Oncology
- 발행국가
- 미국
- 분량
- 8 페이지
- ISSN
- E 1527-7755
P 0732-183X